Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax 3D adjustable TAVR system [1] - All three product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] - The vascular access products saw revenue growth due to the increasing sales of the high-performance DCwire microcatheter, leading to a rapid increase in market share [1] Group 2: Product Performance - The hemorrhagic products benefited from the successful launch of the YonFlow blood flow-directed stent, which drove revenue growth for that product line [1] - Revenue growth in the ischemic product segment was mainly due to increased sales of the Syphonet thrombectomy stent and Tethys AS thrombectomy catheter [1] - Despite a price reduction in balloon dilation catheters following the implementation of volume-based procurement in the second half of 2025, sales volume significantly increased, particularly for the Fastunnel delivery balloon dilation catheter, keeping overall revenue stable compared to 2024 [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - With the registration application for the TaurusTrio transcatheter aortic valve system approved by the National Medical Products Administration in December 2025, the company anticipates a full commercialization in the Chinese aortic regurgitation market [2]

Core Viewpoint - Peijia Medical-B (09996) has seen a significant increase in stock price, attributed to the chairman's confidence demonstrated through share buybacks and the recent approval of its TaurusTrio device for market entry [1][2] Group 1: Company Developments - Peijia Medical's stock rose over 6%, with a cumulative increase of over 22% in December [1] - The chairman, Dr. Zhang Yi, plans to invest up to 15 million HKD in purchasing company shares from the open market [1] - The TaurusTrio transcatheter aortic valve system has received approval from the National Medical Products Administration, marking it as the first integrated positioning key transcatheter aortic valve regurgitation intervention device approved in China [1] Group 2: Industry Position - According to CITIC Securities, Peijia Medical holds a leading position in the domestic heart valve intervention market, with positive clinical feedback and increasing market share for its TAVR products since commercialization [2] - The company has a comprehensive product development layout in aortic, mitral, and tricuspid valve treatment areas, which helps solidify its leading position in the heart valve sector [2] - Peijia Medical anticipates the approval and commercialization of three major products by the end of 2025 to 2026, which is expected to drive a rapid recovery in overall performance [2] - The company's neurointerventional business is among the top domestic players, with a promising growth trend expected as the product pipeline continues to expand and commercialization progresses [2]

Core Viewpoint - Peijia Medical (09996) has seen a significant increase in its stock price, rising over 22% in December, with a current price of 6.35 HKD and a trading volume of 10.9 million HKD [1] Group 1: Company Developments - On December 5, Peijia Medical announced that Chairman Dr. Zhang Yi plans to invest up to 15 million HKD to buy back company shares in the open market [1] - On December 11, Peijia Medical received approval from the National Medical Products Administration for its TaurusTrio transcatheter aortic valve system, marking it as the first integrated positioning key transcatheter aortic valve regurgitation (AR) intervention device approved in China [1] Group 2: Market Position and Future Outlook - According to a report from CITIC Securities, Peijia Medical holds a leading position in the domestic heart valve intervention market, with positive clinical feedback and rapid market share growth since the commercialization of its TAVR products [1] - The company has a comprehensive product development pipeline in the aortic, mitral, and tricuspid valve treatment areas, which is expected to strengthen its leading position in the heart valve sector [1] - Peijia Medical anticipates the approval and commercialization of three major products in China by the end of 2025 to 2026, which will support a rapid recovery in overall performance [1] - The company's neurointerventional business is among the top domestic players, and with a continuously enriching product pipeline and ongoing commercialization of certified products, it is expected to maintain a trend of rapid development [1]

Market Performance - The Hong Kong stock market experienced a strong upward trend on December 12, with the Hang Seng Index rising by 446.28 points, or 1.75%, closing at 25,976.79 points [1] - The Hang Seng Tech Index increased by 103.46 points, or 1.87%, closing at 5,638.05 points [1] - The China Enterprises Index rose by 145.07 points, or 1.62%, closing at 9,079.35 points [1] - The Red Chip Index gained 47.77 points, or 1.16%, closing at 4,150.4 points [1] Sector Performance - Technology stocks saw significant gains, with NetEase rising over 4%, and Tencent, Alibaba, and Lenovo increasing by over 2% [1] - Power equipment stocks surged, with Dongfang Electric rising over 13% [1] - Gold stocks generally rose, with Zijin Mining International increasing by over 3% [1] - Chinese brokerage stocks saw a late rally, with China Galaxy rising over 6% [1] - Insurance stocks strengthened in the afternoon, with China Pacific Insurance and China Life both rising over 5% [1] - AIGC concept stocks and real estate blue-chip stocks also saw gains [1] - However, the Everbright system and tobacco stocks declined [1] Company News - Hong Kong Electronic Commerce reported a total merchandise transaction value of HKD 636 million in November, a year-on-year decrease of 7.4% [2] - BOE Technology Group signed a total product processing agreement with its Vietnam subsidiary [2] - China Galaxy completed the issuance of a short-term corporate bond worth 4 billion yuan [2] - Cloudy Technology plans to establish a joint venture focusing on innovative robotic solutions [3] - Cloudtop New Horizon signed a commercialization service agreement with Haisen Bio [3] - Peijia Medical's TaurusTrio transcatheter aortic valve system received approval from the National Medical Products Administration [3] - China Antibody's SM17 new drug research application was accepted by the National Medical Products Administration [4] - Hengyi Holdings plans to undergo capital restructuring and fundraising activities [5] Institutional Insights - GF Securities noted that the Hong Kong stock market is more sensitive to external risks, with potential rebounds expected in mid to late December and early January [6] - Dongwu Securities believes the market is still in a left-side phase, requiring patience for a rebound [6] - Everbright Securities indicated that while there is significant room for growth compared to previous bull markets, the current market may lack strong catalysts [6] - Guoxin Securities highlighted that the recent net inflow of southbound funds into the Hong Kong market exceeded 110 billion yuan in November, indicating strong liquidity and a willingness to invest at lower levels [6] - The forecast for the Hong Kong market in 2026 is expected to range between 30,000 and 32,000 points [6] Industry Trends - The ice and snow economy is emerging as a new growth point, encompassing ice and snow sports, tourism, equipment, and culture [7] - This sector is characterized by a long industrial chain, significant spillover effects, and high social benefits, contributing to regional economic development [7] - The increasing popularity of ice and snow sports and tourism is transforming "cold resources" into a "hot economy," leading to rapid growth in the ice and snow industry [7] - There is a recommendation to focus on ice and snow sports brands with marginal improvements and stable dividend-paying leading companies [7]

Core Viewpoint - Peijia Medical-B (09996) shares rose nearly 7%, currently up 6.88% at HKD 6.21, with a trading volume of HKD 7.4878 million [1] Group 1: Company Developments - Peijia Medical announced that on December 11, it received approval from the National Medical Products Administration of the People's Republic of China for the registration application of the TaurusTrio Transcatheter Aortic Valve (TAV) system [1] - The TaurusTrio TAV system is developed and manufactured by the company under an exclusive license obtained from JenaValve Technology, Inc. for the Trilogy Transcatheter Heart Valve (THV) system [1] - The Trilogy THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial surgeries in real-world clinical practice as of the announcement date [1] Group 2: Market Implications - The company anticipates that the successful launch of the TaurusTrio TAV system in China will provide a safe and effective treatment option for patients with severe aortic regurgitation (AR), addressing a significant unmet clinical need [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of the People's Republic of China for the registration application of the TaurusTrio Transcatheter Aortic Valve (TAV) system, which is designed to treat patients with severe aortic regurgitation (AR) [1] Group 1: Product Development and Approval - The TaurusTrio TAV system is developed and manufactured based on an exclusive license obtained from JenaValve Technology, Inc. for the Trilogy Transcatheter Heart Valve (THV) system [1] - The system is specifically designed for treating patients with severe aortic regurgitation via the transfemoral approach, addressing a significant unmet clinical need [1] Group 2: Technical Features - The TaurusTrio TAV system utilizes proprietary anchoring technology that allows for secure fixation even in the absence of calcified tissue, which is a common challenge in AR patients [1] - The system ensures proper alignment of the valve with the native leaflets, enhancing the effectiveness of the treatment [1] Group 3: Market Potential - The Trilogy THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial procedures in real-world clinical practice as of the date of the announcement [1] - The successful launch of the TaurusTrio TAV system in China is expected to provide a safe and effective treatment option for patients suffering from severe AR, fulfilling a significant clinical demand in the market [1]